Last reviewed · How we verify
LhRH-antagonist
LhRH antagonists block luteinizing hormone-releasing hormone receptors to suppress gonadotropin secretion and reduce sex hormone production.
LhRH antagonists block luteinizing hormone-releasing hormone receptors to suppress gonadotropin secretion and reduce sex hormone production. Used for Prostate cancer (hormone-sensitive), Endometriosis, Uterine fibroids.
At a glance
| Generic name | LhRH-antagonist |
|---|---|
| Also known as | Degarelix 120 MG |
| Sponsor | Turku University Hospital |
| Drug class | GnRH/LhRH antagonist |
| Target | GnRH receptor (LhRH receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
LhRH antagonists competitively bind to GnRH receptors in the pituitary gland, immediately blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to rapid suppression of testosterone in males and estrogen in females, without the initial testosterone surge seen with GnRH agonists. The mechanism is used therapeutically to suppress sex hormone-dependent conditions.
Approved indications
- Prostate cancer (hormone-sensitive)
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Fatigue
Key clinical trials
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (NA)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LhRH-antagonist CI brief — competitive landscape report
- LhRH-antagonist updates RSS · CI watch RSS
- Turku University Hospital portfolio CI